Navigating the treatment of RRMM with BCMA-directed therapies: Updates from COMy, ASCO and EHA 2025

touchCONGRESS for touchHAEMATOLOGY and touchONCOLOGY Listen to multiple myeloma expert Prof. Philippe Moreau review key data for BCMA-targeting agents in the treatment of relapsed/refractory multiple myeloma presented at the international Controversies in Multiple Myeloma (COMy), American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) 2025 congresses. Prof. Moreau is then joined by fellow experts Dr Paola Neri and Prof. Hermann Einsele to discuss how these data may apply in clinical practice. Overview Data reviews with Prof. Moreau Expert panel discussions with Prof. Moreau, Dr Neri and Prof. Einsele on the themes below Clinical themes Approved BCMA-directed therapeutic approaches  Practical application of BCMA-directed therapies Future of treating RRMM: Emerging BCMA-directed therapies and combinations The internationally renowned multiple myeloma expert faculty Prof. Philippe Moreau: Nantes, France Prof. Hermann Einsele: Würzburg, Germany Dr Paola Neri: Calgary, AB, Canada This touchPODCAST is for HCPs outside of the USA.  This activity is funded by an independent medical education grant from GSK. This activity is provided by touchIME. touchIME is an EBAC® accredited provider. For further information, visit our website: www.touchHAEMATOLOGY.com and www.touchONCOLOGY.com